U.S., July 23 -- ClinicalTrials.gov registry received information related to the study (NCT07076225) titled 'Ultra-Short Regimen for Elderly DS-TB' on June 30.
Brief Summary: Tuberculosis (TB) remains one of the leading global public health concerns and is among the top ten causes of death from a single infectious agent. China ranks third worldwide in total TB burden, with a substantial proportion of cases classified as drug-susceptible TB (DS-TB). Despite the availability of effective standard treatment regimens, the current 6-month therapy duration poses challenges in terms of patient adherence, resource allocation, and overall treatment success.
In recent years, ultrashort-course regimens for DS-TB have been proposed and evaluated in c...